BASF Newtrition, a subsidiary of German chemicals giant BASF, has launched a new absorption technology designed to improve the delivery of omega 3 fatty acids from a single concentrated dose, such as a supplement pill.
According to BASF, its Accelon technology improved eicosapentaenoic acid (EPA) absorption by 6.4 times when compared to a dose without it and the absorption of docosahexaenoic acid (DHA) by 11.5 times, Nutraingredients wrote on 21 November.
BASF researchers said the discovery could negate the need for a high-fat meal pre-supplementation to enable sufficient omega 3 absorption.
“Based on an individual’s omega 3 index before starting to supplement, we can fairly accurately tell which dose is needed to get the index up to a new and safer level: 8% has been proposed as the target to strive for,” said Øyvind Ihle, team leader at Newtrition Omega-3.
“By maximising absorption, Accelon shifts the paradigm. We can stop talking about intake but rather focus on uptake and status. It should therefore be used to boost people’s index further, rather than skimping on the dosage to little or no effect. Only then can people experience the benefit they’re hoping for,” he added.
Accelon was a mix of omega 3 oils formulated with pre-emulsifiers, highly concentrated omega 3 ethyl esters, food-grade carrier oils and antioxidants, reported Nutraingredients.
When the capsule dissolved, the contents would be spontaneously formed into an emulsion containing “billions of omega 3 micro droplets”, which would move into the intestine where their more accessible surface allowed for a higher EPA/DHA digestion rate and absorption when compared to standard omega 3 oils.
According to Ihle, the higher absorption potential could improve consumer confidence in the efficiency of omega 3 products and encourage more people to try these supplements.
“One of the biggest barriers for non- and lapsed users is the perception of efficacy. In our consumer research, Accelon clearly resonates among these consumers due to the perception of a ‘smarter technology’ that works at cellular levels and gets more omega 3 to where it’s needed, therefore credibly delivering the health benefits claimed,” he explained.
Ihle added that BASF would continue to research Accelon’s potential with other nutrients that were difficult for the body to absorb, such as resveratrol and curcumin.